O&d Biotech Group Co., Limited

This early-stage trial tests a new cell therapy called O&D-001 for people with multiple myeloma that has come back or stopped responding to treatment. The therapy uses a patient's own immune cells, modified to attack two cancer targets (BCMA and GPRC5D). The study will enroll 18 …